TABLE 3.
Effects of torcetrapib on TRL apoB-48 kinetic parameters
| Torcetrapib Alone |
Atorvastatin + Torcetrapib |
|||
| Parameter and Study Phasea | 120 mg once daily (n = 9) | 120 mg twice daily (n = 6) | 120 mg once daily (n = 9) | P, Statin vs Nonstatinb |
| ApoB-48 PS (mg) | ||||
| Placebo | 18.5 ± 4.1 | 21.3 ± 5.8 | 7.4 ± 1.7 | 0.03 |
| Torcetrapib | 9.0 ± 2.9 | 14.8 ± 4.5 | 6.3 ± 1.6 | 0.64 |
| Change (%) | −49 ± 9 | −30 ± 6 | −3 ± 14 | |
| P value | 0.007 | 0.01 | 0.47 | |
| ApoB-48 FCR (pools/day) | ||||
| Placebo | 6.8 ± 0.8 | 7.0 ± 1.0 | 7.7 ± 1.0 | 0.55 |
| Torcetrapib | 7.1 ± 0.9 | 7.1 ± 1.6 | 7.1 ± 1.2 | 0.87 |
| Change (%) | 14 ± 17 | 4 ± 19 | −5 ± 12 | |
| P value | 0.83 | 0.82 | 0.37 | |
| ApoB-48 PR (mg/kg/day) | ||||
| Placebo | 1.42 ± 0.30 | 1.60 ± 0.36 | 0.57 ± 0.13 | 0.04 |
| Torcetrapib | 0.69 ± 0.21 | 1.07 ± 0.25 | 0.46 ± 0.09 | 0.59 |
| Change (%) | −49 ± 8 | −27 ± 17 | −12 ± 12 | |
| P value | 0.005 | 0.13 | 0.20 | |
FCR, fractional catabolic rate; PR, production rate; PS, pool size; TRL, triglyceride-rich lipoprotein. Boldface indicates significance.
a
Data are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired t-test on log-transformed data.
b
Significance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts on placebo and torcetrapib 120 mg once daily was tested by a two-independent sample t-test.